 AUSTIN, TX DURHAM, NC, Oct. 05, 2022 GLOBE NEWSWIRE -- Shattuck Labs, Inc. Shattuck NASDAQ: STTK, a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will present a poster on its bispecific Gamma Delta T Cell Engager GADLEN platform at SITCs 37th Annual Meeting being held November 8th 12th, 2022, virtually and in-person in Boston. 